{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:34Z","timestamp":1790963014714,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02776-8","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T04:31:00Z","timestamp":1707021060000},"page":"1245-1261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of Patients with COPD Treated with ICS\/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI)"],"prefix":"10.1007","volume":"41","author":[{"given":"Meredith","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0624-1022","authenticated-orcid":false,"given":"Noelle N.","family":"Gronroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-6508","authenticated-orcid":false,"given":"Lydia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1990","authenticated-orcid":false,"given":"Phani","family":"Veeranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Igboekwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Kahle-Wrobleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reynold","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"key":"2776_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/COPD.S347735","volume":"17","author":"J Tkacz","year":"2022","unstructured":"Tkacz J, Evans KA, Touchette DR, et al. PRIMUS \u2013 Prompt Initiation of Maintenance Therapy in the US: a real-world analysis of clinical and economic outcomes among patients initiating triple therapy following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:329\u201342.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2776_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. 2023. https:\/\/goldcopd.org\/2023-gold-report-2\/. Accessed 13 July 2023."},{"issue":"2","key":"2776_CR3","first-page":"57","volume":"15","author":"DL Larsen","year":"2022","unstructured":"Larsen DL, Gandhi H, Pollack M, Feigler N, Patel S, Wise RA. The quality of care and economic burden of COPD in the United States: considerations for managing patients and improving outcomes. Am Health Drug Benefits. 2022;15(2):57\u201364.","journal-title":"Am Health Drug Benefits"},{"key":"2776_CR4","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2022 report. 2022. https:\/\/goldcopd.org\/wp-content\/uploads\/2021\/12\/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed 22 Aug 2023."},{"key":"2776_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.019","volume":"150","author":"RH Stanford","year":"2019","unstructured":"Stanford RH, Parker ED, Reinsch TK, Buikema AR, Blauer-Peterson C. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS\/LABA. Respir Med. 2019;150:1\u20137.","journal-title":"Respir Med"},{"key":"2776_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101855","volume":"59","author":"L Calzetta","year":"2019","unstructured":"Calzetta L, Di Marco F, Blasi F, et al. Impact of ICS\/LABA and LABA\/LAMA FDCs on functional and clinical outcomes in COPD: a network meta-analysis. Pulm Pharmacol Ther. 2019;59:101855.","journal-title":"Pulm Pharmacol Ther"},{"key":"2776_CR7","unstructured":"US Food and Drug Administration. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation use. Highlights of prescribing information. Revised: 2022. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209482s013lbl.pdf. Accessed 13 July 2023."},{"issue":"4","key":"2776_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2776_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/15412555.2020.1817357","volume":"17","author":"RH Stanford","year":"2020","unstructured":"Stanford RH, Engel-Nitz NM, Bancroft T, Essoi B. The identification and cost of acute chronic obstructive pulmonary disease exacerbations in a United States population healthcare claims database. COPD. 2020;17(5):499\u2013508.","journal-title":"COPD"},{"issue":"2","key":"2776_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/pds.4372","volume":"27","author":"L Pazzagli","year":"2018","unstructured":"Pazzagli L, Linder M, Zhang M, et al. Methods for time-varying exposure related problems in pharmacoepidemiology: an overview. Pharmacoepidemiol Drug Saf. 2018;27(2):148\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2776_CR11","unstructured":"Agency for Healthcare Research and Quality. Clinical classifications software (CCS) for ICD-10-PCS (beta version). 2019. https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs10\/ccs10.jsp. Accessed 13 July 2023."},{"issue":"6","key":"2776_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"key":"2776_CR13","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.2147\/COPD.S382405","volume":"17","author":"C Gessner","year":"2022","unstructured":"Gessner C, Trinkmann F, Bahari Javan S, et al. Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany \u2013 the TriOptimize study. Int J Chron Obstruct Pulmon Dis. 2022;17:3019\u201331.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2776_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/COPD.S367701","volume":"17","author":"RA Panettieri","year":"2022","unstructured":"Panettieri RA, Camargo CA Jr, Cheema T, et al. Effect of recent exacerbation history on the efficacy of once-daily single-inhaler fluticasone furoate\/umeclidinium\/vilanterol triple therapy in patients with chronic obstructive pulmonary disease in the FULFIL trial. Int J Chron Obstruct Pulmon Dis. 2022;17:2043\u201352.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2776_CR15","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2017 report. 2017. https:\/\/goldcopd.org\/wp-content\/uploads\/2017\/02\/wms-GOLD-2017-FINAL.pdf. Accessed 21 Nov 2023."},{"issue":"2","key":"2776_CR16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2013.1113","volume":"11","author":"SJ Rolnick","year":"2013","unstructured":"Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54\u201365.","journal-title":"Clin Med Res"},{"key":"2776_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.rmed.2017.06.007","volume":"129","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117\u201323.","journal-title":"Respir Med"},{"issue":"9","key":"2776_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/thx.2007.086041","volume":"63","author":"J Bourbeau","year":"2008","unstructured":"Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831\u20138.","journal-title":"Thorax"},{"issue":"10","key":"2776_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase\u00a03 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2776_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"2776_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","volume":"198","author":"KM Kunisaki","year":"2018","unstructured":"Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2776_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1164\/rccm.201710-2029OC","volume":"198","author":"KJ Rothnie","year":"2018","unstructured":"Rothnie KJ, M\u00fcllerov\u00e1 H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"2776_CR23","first-page":"235","volume":"5","author":"AJ Guarascio","year":"2013","unstructured":"Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235\u201345.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"1","key":"2776_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1378\/chest.14-2434","volume":"148","author":"DM Mannino","year":"2015","unstructured":"Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138\u201350.","journal-title":"Chest"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02776-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02776-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02776-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:16:01Z","timestamp":1708452961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02776-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2776"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02776-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meredith McCormack has received consulting fees from Aridis Pharmaceuticals, GSK, Boehringer Ingelheim, and MCG Diagnostics and has received royalties for authorship from UpToDate. Meredith McCormack has also served on the medical advisory board for ndd Technology. Rosirene Paczkowski, Stephen G. Noorduyn, Emmeline Igboekwe, and Kristin Kahle-Wrobleski are employees of, and\/or hold stocks\/shares, in GSK. Lydia Lee is a university worker hired by GSK. Noelle N. Gronroos, Phani Veeranki, and Mary G. Johnson are employees of, and hold stocks\/shares in, Optum, which received funding from GSK to conduct this study. Reynold Panettieri has received research grants from AZ, RIFM, TEVA, MedImmune, and AgoMab and has featured on advertisement boards for AZ, RIFM Genentech, and Praesidia. Reynold Panettieri has also worked as a speaker for AZ, Sanofi, and Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study complied with all applicable laws regarding subject privacy, no subject identifiers are included in these results, and no direct subject contact or primary collection of individual human subject data took place. All study results are in tabular form and are presented as aggregate analyses that omit subject identification; therefore, informed consent and ethics committee or institutional review board approval were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}